Key result
Ivabradine offers a stable angina treatment option for patients with beta-blocker intolerance or contraindications.
Ivabradine provides a novel heart rate-lowering treatment option for stable angina patients who cannot tolerate or have contraindications to beta-blockers.
May support ivabradine consideration in beta-blocker intolerant angina; leaves open need for prospective RCTs before practice change.
Ivabradine is not only the first of a new class of selective If channel inhibitors, but is also the first new medical treatment for stable angina to be approved in Europe for 10 years. By selectively reducing heart rate without adversely affecting myocardial contractility or blood pressure, ivabradine offers a valuable new option for patients with stable angina in whom beta-blockers are not tolerated or are contraindicated.
No takes yet. Share an insight, caveat, or question.
Ian Menown (2007) conducted a review in stable angina. Ivabradine was evaluated. Ivabradine, a selective If channel inhibitor, offers a new treatment option for stable angina in patients who cannot tolerate or have contraindications to beta-blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: